Stereotaxis Inc   (STXS)
Other Ticker:  
Price: $2.7000 $-0.17 -5.923%
Day's High: $2.89 Week Perf: -8.78 %
Day's Low: $ 2.50 30 Day Perf: 33.66 %
Volume (M): 572 52 Wk High: $ 3.29
Volume (M$): $ 1,544 52 Wk Avg: $1.82
Open: $2.89 52 Wk Low: $1.33

 Market Capitalization (Millions $) 219
 Shares Outstanding (Millions) 81
 Employees -
 Revenues (TTM) (Millions $) 29
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 3

Stereotaxis Inc
Stereotaxis Inc. is a medical technology company that specializes in the field of robotic cardiac ablation. The company designs and manufactures systems that use robotic control and navigation technologies for the treatment of cardiac arrhythmias. The Stereotaxis Robotic Magnetic Navigation System allows physicians to remotely navigate and position catheters within the heart using powerful magnets and precise robotic control, providing greater precision and safety during procedures. Stereotaxis Inc. aims to improve patient outcomes and enhance the efficiency of cardiac procedures through their innovative technologies.

   Company Address: 710 North Tucker Boulevard St. Louis 63101 MO
   Company Phone Number: 678-6100   Stock Exchange / Ticker: NYSEAMER STXS
   STXS is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Breaking Boundaries: Intermountain Health Becomes Utah's Pioneer in Robotic Heart Care Advancements

Published Thu, Feb 22 2024 9:15 PM UTC

Intermountain Health Pioneers Revolutionary Robotic Technology in Heart Care AdvancementsIntermountain Medical Center, located in the heart of Utah, is set to revolutionize the field of cardiovascular care with the adoption of advanced robotic technology. This landmark makes Intermountain the first hospital in both the region and the state to embrace this cutting-edge innova...

Clinical Study

Advancements in Catheter Ablation Technology: The Game-Changing Magnetic Interventional Catheter - MAGiC

Published Mon, Jan 8 2024 1:34 PM UTC

Abstract:This article presents a comprehensive review of the recent advancements in catheter ablation technology, with a focus on the groundbreaking Magnetic Interventional Catheter (MAGiC) developed by Stereotaxis. The primary objective is to explore the efficacy and safety of MAGiC in the treatment of cardiac arrhythmias. Through a detailed analysis of the recent study con...

Stereotaxis Inc

Stereotaxis Inc's Bewildering Revenue Growth Fails to Deliver Profitability in Q2 2023

Over the last five trading days, Stereotaxis Inc has experienced a decline in stock performance, with a decrease of -0.64%. As a result, the year-to-date performance of the company now stands at -26.19%. It is worth noting, however, that the stock is still trading 16.5% above its 52-week low.
Looking at the financials for the April to June 30, 2023 time-frame, Stereotaxis Inc reported a loss of $-0.07 per share, which is the same as the previous year. Additionally, the company's revenue increased by 16.824% to $7.19 million compared to $6.15 million in the same quarter of the previous year. Sequentially, revenue also grew by 9.759% from $6.55 million.
When compared to other companies in the Medical Equipment & Supplies sector, Stereotaxis Inc showed stronger top-line growth in the second quarter of 2023. Many businesses in this sector experienced a top-line growth of 3.90% from the second quarter of 2022.
In terms of net deficit, Stereotaxis Inc reported a decrease from $-5.134 million in the comparable quarter of the previous year to $-4.957 million in the April to June 30, 2023 time-frame. This suggests an improvement in the company's financials.

Stereotaxis Inc

Stereotaxis Inc's Top-Line Contracts in Q1 2023, Highlighting Concerning Financial Performance

Stereotaxis Inc has recorded a cumulative net loss of $-20 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -49.16%. The healthcare sector saw 409 other companies with a higher ROI, which is a cause for concern for investors.
The ROI ranking has progressed in the Mar 31, 2023 quarter, moving up to 2788 from the total ROI ranking in the fourth quarter of 2022 at 4296. However, this does not change the fact that Stereotaxis Inc still falls behind many other healthcare companies in terms of ROI.
For the fiscal span closing March 31, 2023, STXS increased its loss per share to $-0.07 per share from the prior reporting period, which is higher than the previous year's loss of $-0.06 per share. The revenue decreased by -6.949% to $6.55 million from $7.04 million in the similar reporting period a year before, and sequentially Revenue deteriorated by -10.314% from $7.30 millionStereotaxis Inc realized a net loss of $-5.347 million for the fiscal span closing March 31, 2023, higher than $-4.086 million a year ago, which shows a continuous trend towards negative financial performance.
Investors should take note of these results and carefully consider their portfolios, as Stereotaxis Inc is expected to report its next financial results on August 10, 2023.


Stereotaxis Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com